Buying Caliper, PerkinElmer Will Gain Suite of Array-Related Tools | GenomeWeb

By Justin Petrone

PerkinElmer stands to gain a number of array-related tools through its planned acquisition of Caliper Life Sciences.

The two companies last week said PerkinElmer would buy Caliper for $600 million in stock. The deal is expected to close before the end of the year.

While Caliper has never been a pure-play array firm, it does sell a menu of products that are widely used in microarray laboratories. These include instruments for sample preparation, liquid handling, and imaging.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.